Lafayette, CA (March, XX, 2026) — The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit advancing research, education, and advocacy around psychedelics and cannabis, …
Vienna, Austria; March 9, 2026 —The Multidisciplinary Association for Psychedelic Studies (MAPS) will send senior academics, advocates, Veterans, and policy experts to the 69th session of the United …
Washington, DC; February 4, 2026 — With the United States in a pivotal election year, the Multidisciplinary Association for Psychedelic Studies (MAPS) released its Policy Guidebook, a robust resource …
February 2, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announces a formal research partnership with Columbia University to study how practitioners are facilitating MDMA-assisted …
January 14, 2026 — In October 2025, Joe Green and Miriam Volat resigned their positions as members of the MAPS Board of Directors. Mr. Green joined the MAPS board in December 2020 and — among other …
December 23, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the completion of a therapy training initiative supporting clinicians participating in a Department of Defense …
The executive order to reschedule cannabis marks a symbolic victory and a recalibration of decades of federal misclassification. Reclassifying cannabis as a Schedule III substance is a long-overdue acknowledgment …
Using funding provided by the Ohio Department of Behavioral Health, the Center for Psychedelic Drug Research and Education (CPDRE) will equip more than 127,000 Ohio professionals with skills in psychedelic …
San Jose, CA | October 6, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization at the vanguard of the psychedelic movement since 1986, is partnering …
September 9, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit organization at the vanguard of the psychedelic movement since 1986, today announced that its …
San Jose, CA; September 4, 2025 — In August 2024, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to Lykos Therapeutics, declining to approve MDMA-assisted therapy …
August 27, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced today that it has selected Changemark Research + Evaluation (Changemark) as its contract research organization …
